

Claims

1. Use of a dopamine receptor agonist or a pharmaceutically acceptable salt thereof for producing a pharmaceutical preparation for the treatment of cutaneous tumours, warts and scars.
2. Use according to Claim 1, characterised in that the dopamine receptor agonist is a dopamine D<sub>2</sub> receptor agonist.
3. Use according to Claim 1 or 2, characterised in that the dopamine receptor agonist is bromocriptine, pergolide, selegiline, ropirinole, pramipexole or cabergolide.
4. Use according to one of Claims 1 to 3, characterised in that in the case of the cutaneous tumours it is a question of cutaneous tumours of the preliminary stage of cancer or non-metastasising carcinomas of the skin.
5. Use according to one of Claims 1 to 4, characterised in that in the case of the cutaneous tumours it is a question of actinic keratoses, basalioma or bowenoids.
6. Use according to one of Claims 1 to 3, characterised in that in the case of the warts it is a question of interdigital warts, plane warts, plantar warts, vulgar warts or condyloma.
7. Use according to one of the preceding claims, characterised in that the pharmaceutical preparation is present in the form of a topical preparation.
8. Use according to Claim 7, characterised in that the pharmaceutical preparation contains a dopamine receptor

REPLACED BY  
ART 34 AMDT

agonist or a pharmaceutically acceptable salt thereof in a quantity from 0.1 wt.% to 10 wt.%, relative to the pharmaceutical preparation.

5 9. Use according to Claim 8, characterised in that the pharmaceutical preparation contains a dopamine receptor agonist or a pharmaceutically acceptable salt thereof in a quantity from 0.25 wt.% to 0.5 wt.%, relative to the pharmaceutical preparation.

10

10. Use according to Claim 9, characterised in that the pharmaceutical preparation contains bromocriptine or a pharmaceutically acceptable salt thereof in a quantity from 0.25 wt.% to 0.5 wt.%, relative to the pharmaceutical

15

preparation.

11. Use according to one of Claims 7 to 10, characterised in that the pharmaceutical preparation is present in the form of an ointment, a paste, a lotion, a creme or a gel.

20

12. Use according to one of Claims 7 to 11, characterised in that the pharmaceutical preparation contains conventional adjuvants, excipients and/or diluents.

25

13. Use according to one of the preceding claims, characterised in that the pharmaceutical preparation is applied locally onto the affected cutaneous areas once or several times a day.

30

14. Use according to one of the preceding claims, characterised in that the use of the pharmaceutical preparation is undertaken together with a medicinal treatment that is matched to the disease.

15. Use according to one of the preceding claims, characterised in that the use of the topical pharmaceutical preparation is undertaken together with an oral adjuvant therapy involving a dopamine receptor agonist.

5

16. Use according to one of the preceding claims, characterised in that the pharmaceutical preparation contains dimethyl sulfoxide.

10 17. Use according to Claim 16, characterised in that the pharmaceutical preparation contains 5-20 wt.% dimethyl sulfoxide, preferably 10-15 wt.%, relative to the pharmaceutical preparation.

REPLACED BY  
ART 34 AMDT